In the last decade, significant technical development has been achieved providing wide range of availability of LINAC-based radiosurgery. Several clinical trials prove the advantage of stereotactic radiotherapy (stereotactic ablative radiotherapy (SABR) Stereotactic body radiotherapy (SBRT), fractionated stereotactic radiosurgery, and radiotherapy (fSRS, SRT) of single and oligometastatic cancers in different locations. (COMET 1, COMET2, STAMPEDE, NHS England Commissioning through Evaluation scheme, SINDAS). Recent research on novel imaging, such as PSMA PET/CT, 4DCT/PETCT, and advanced sequences of MRI, provides superior accuracy for target definition and target motion management. Fractionated SBRT, SRS, and SRT delivery enable the use of adaptive radiation approaches. Optimization of the standard operating procedures of stereotactic radiotherapy may result in improvement of the effectivity and the therapeutic index.
This Research Topic aims to collect studies to update and discuss the recent advances in stereotactic radiotherapy addressing important technical and clinical questions on LINAC-based hypofractionated high dose delivery for the treatment of oligometastatic disease. Indication, treatment preparation including advanced imaging for target definition of SBRT, SRT for diverse cancer types such as prostate, lung, breast, kidney, liver, pancreatic malignancies, and less frequent tumors such as melanoma, sarcoma could be studied in different clinical situations like early-stage cancer, oligo-site progression and local recurrence in pretreated location. Optimization of treatment delivery (time and volume determination, on-board and repeated imaging, target motion monitoring, and management) can be evaluated along with outcome results.
We welcome submissions on, but not limited to, the following themes:
- Positioning, immobilization, and target motion detection in the preparatory phase of SABR, SRS
- Use of advanced imaging for target definition, and motion follow up
- Fractionation, timing, and dosage of radiation
- Radiation delivery and imaging techniques, quality assurance
- Evaluation of the treatment outcome in correlation to the clinical factors and radiation parameters
Original Research, in the above-listed topics, is preferred as the manuscript type.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
In the last decade, significant technical development has been achieved providing wide range of availability of LINAC-based radiosurgery. Several clinical trials prove the advantage of stereotactic radiotherapy (stereotactic ablative radiotherapy (SABR) Stereotactic body radiotherapy (SBRT), fractionated stereotactic radiosurgery, and radiotherapy (fSRS, SRT) of single and oligometastatic cancers in different locations. (COMET 1, COMET2, STAMPEDE, NHS England Commissioning through Evaluation scheme, SINDAS). Recent research on novel imaging, such as PSMA PET/CT, 4DCT/PETCT, and advanced sequences of MRI, provides superior accuracy for target definition and target motion management. Fractionated SBRT, SRS, and SRT delivery enable the use of adaptive radiation approaches. Optimization of the standard operating procedures of stereotactic radiotherapy may result in improvement of the effectivity and the therapeutic index.
This Research Topic aims to collect studies to update and discuss the recent advances in stereotactic radiotherapy addressing important technical and clinical questions on LINAC-based hypofractionated high dose delivery for the treatment of oligometastatic disease. Indication, treatment preparation including advanced imaging for target definition of SBRT, SRT for diverse cancer types such as prostate, lung, breast, kidney, liver, pancreatic malignancies, and less frequent tumors such as melanoma, sarcoma could be studied in different clinical situations like early-stage cancer, oligo-site progression and local recurrence in pretreated location. Optimization of treatment delivery (time and volume determination, on-board and repeated imaging, target motion monitoring, and management) can be evaluated along with outcome results.
We welcome submissions on, but not limited to, the following themes:
- Positioning, immobilization, and target motion detection in the preparatory phase of SABR, SRS
- Use of advanced imaging for target definition, and motion follow up
- Fractionation, timing, and dosage of radiation
- Radiation delivery and imaging techniques, quality assurance
- Evaluation of the treatment outcome in correlation to the clinical factors and radiation parameters
Original Research, in the above-listed topics, is preferred as the manuscript type.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
